![](https://femtechinsider.com/wp-content/uploads/2022/08/aima-endometrosis-diagnostics.jpg)
AIMA Laboratories (AIMA), a preclinical FemTech company dedicated to developing new products that fill current gaps in gynecological health, is teaming up with Innovative Health Diagnostics (IHD), a CLIA- and FDA-certified lab, to develop and deliver a new and reliable at-home blood test to detect endometriosis.
“We’re thrilled to partner with AIMA to offer a service that provides actionable results and allows millions of women access to early diagnostic tools to detect endometriosis, carving a path to the right care, at the right time and when it’s most convenient,” said David White, IHD CEO and Co-Founder. “At IHD, it is our mission to deliver solutions that provide hope to people struggling with infertility, and our partnership with AIMA further enables that mission.”
The new test identifies certain microRNA biomarkers that are differentially expressed in women with endometriosis compared to women without. The test’s accuracy is comparable to laparoscopy, a type of surgery that is used to get a closer look into a woman’s abdomen and reproductive system. Laparoscopy is used to both diagnose and treat endometriosis, detecting and removing endometrial lesions. Because laparoscopy is a more invasive procedure, it often takes years for women to get tested and treated.
The new IHD-AIMA test will complement laparoscopic procedures. The test will both help eliminate diagnostic delays, enabling a noninvasive way to test for endometriosis, and allow for patients who receive a positive test result to undergo a laparoscopy for treatment potentially years sooner than they would otherwise.
“At AIMA, our mission is to shorten a woman’s path to a healthier tomorrow,” explained Dr. Lauren Foster, Ph.D., Co-Founder and CEO of AIMA. “We’re working to build a world where women actively participate in their own healthcare decisions, starting with endometriosis diagnostics. Our partnership with IHD enables us to serve the millions impacted by this debilitating condition and supplies them with a solution to diagnostic delays.”
AIMA Laboratories is a Canadian, pre-clinical femtech company co-founded by two scientists who have dedicated their professional lives to researching reproductive endocrinology and infertility.